Clinic-Initiated, Twice-Daily Oral Famciclovir for Treatment of Recurrent Genital Herpes: A Randomized, Double-Blind, Controlled Trial | Zendy

Stephen L. Sacks | Zendy; F. Y. Aoki | Zendy; Alain Martel | Zendy; Stephen D. Shafran | Zendy; M. Lassonde | Zendy

Open Access

Clinic-Initiated, Twice-Daily Oral Famciclovir for Treatment of Recurrent Genital Herpes: A Randomized, Double-Blind, Controlled Trial

Author(s) -

Stephen L. Sacks,

F. Y. Aoki,

Alain Martel,

Stephen D. Shafran,

M. Lassonde

Publication year - 2005

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/444457

Subject(s) - famciclovir , penciclovir , medicine , valaciclovir , placebo , randomized controlled trial , dose , dermatology , herpes genitalis , aciclovir , genital herpes , viral disease , herpesviridae , herpes simplex virus , virology , virus , pathology , alternative medicine

Famciclovir, the oral prodrug of penciclovir, is effective for the treatment of recurrent genital herpes. This randomized, clinic-initiated, double-blind trial compared the therapeutic efficacy and safety of treatment with famciclovir at dosages of 125 mg, 250 mg, and 500 mg twice daily for 5 days with placebo in immunocompetent adults with a recurrent episode of genital herpes.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research